Thus, our findings reveal de novo TPD52/ATF6‐mediated signaling activated during ER stress, which is abrogated by APCCdc20‐mediated polyubiquitination of TPD52 at K179, and thereby suggests synergistic strategies for cancer therapy. The gene discussed is TPD52; the disease is cancer.